Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beta Bionics (BBNX) EBITDA (2024 - 2025)

Beta Bionics (BBNX) has disclosed EBITDA for 2 consecutive years, with -$13.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 25.88% to -$13.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$72.9 million through Dec 2025, down 32.89% year-over-year, with the annual reading at -$72.9 million for FY2025, 32.89% down from the prior year.
  • EBITDA hit -$13.4 million in Q4 2025 for Beta Bionics, up from -$14.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$9.7 million in Q3 2024 to a low of -$28.5 million in Q1 2025.